Materials chosen for toxicity, and a line at 0.1 %.
+ The questionWhat does the EU's device regulation require of a device's materials?
A line at 0.1 % inside the rules on materials
Above 0.1 % by weight, a substance of either of two kinds may be present only where its presence is justified. The rule applies to a device that is invasive and in direct contact with the body, to one that administers substances, gases included, to or from the body, and to one that transports or stores them to be administered to the body. The two kinds are substances classified as causing cancer, damaging genes or harming reproduction, and substances identified as disrupting hormones. The rule belongs to the EU's Medical Device Regulation of 5 April 2017, the MDR, and sits in its Annex I, which sets out what a device must meet for safety and performance. The line is point 10.4 of the annex's section 10, on chemical, physical and biological properties, and it comes after three points that set no threshold.
Those three points follow the chain this book traces from the material to the body's response. Point 10.1 asks first for "the choice of materials and substances used, particularly as regards toxicity and, where relevant, flammability", which is the recipe of Chapter 3. Point 10.2 asks that devices be designed, made and packaged so as to minimize the risk from contaminants and residues, so it covers what a material releases and what its processing leaves in it (Chapters 4 to 7). Point 10.3 asks that a device be safe to use with the materials and substances it contacts, gases included, which is the route of Chapter 19. Point 10.4.1 then asks every device to reduce as far as possible the risks of the substances or particles it may release, degradation products and processing residues among them. Only after that general duty does it set a threshold, for two kinds of substance in a narrower set of devices.
Two kinds of substance, counted in the part
Point 10.4.1 names the two kinds. The first are substances that are carcinogenic, mutagenic or toxic to reproduction, which the regulation shortens to CMR substances, and the point lists those "of category 1A or 1B". The second are substances with "endocrine-disrupting properties for which there is scientific evidence of probable serious effects" to human health, identified under REACH, the EU's chemicals law, or under the EU's regulation on biocides (Chapter 11 describes endocrine disruption). For the second kind the MDR relies on an identification made under those laws and decides only what follows for a device. REACH applies alongside the MDR as a separate law and also lists DEHP as a substance of very high concern (Chapter 11). REACH names the hazard of a substance, and the MDR says how much of it a device part may hold without a justification.
Whether the rule reaches the running device depends on the exact wording of its scope. The rule covers a device, or a part or material of it, that is invasive and comes into direct contact with the body, that administers medicines, body liquids or other substances, "including gases", to or from the body, or that transports or stores such substances to be administered to the body. In such a part a listed substance may exceed 0.1 % by weight only with a justification under point 10.4.2, and the regulation writes the threshold as "0,1 % weight by weight (w/w)". The running device does not enter the body, but its gas pathway delivers humidified air to the patient's airway for hours each night (Chapter 2). Point 10.4.1 names gases among the substances a device administers, as point 10.3 names them among those it contacts, so point 10.4.1 applies to the pathway's foam, hose, water chamber and mask.
The line is a concentration in the part or material, not an amount that reaches the patient, so it says nothing about the dose of Chapter 14. A substance below it is still judged by the risk assessment of Chapters 14 and 15, and point 10.2's duty to minimize the risk from residues still applies to it.
- The line. 0.1 % by weight is 1 g in each kilogram of material, or 1,000 mg/kg.
- An ingredient. PVC softened with DEHP holds about 30 % to 40 % of it by weight (Chapter 4), which is 300 to 400 times the line. DEHP is among the phthalates of SCHEER's guidelines (below).
- A residue. BPA is a residue of polycarbonate and polysulfone (Chapter 3), and SCENIHR's 2015 opinion on BPA reports up to 12.2 mg of it extracted from each kilogram of a dialyzer's material. That is 1,000 divided by 12.2, or about 80 times below the line. An extraction gives what came out, so the material held at least that much.
- The result. In a device the rule covers, a plasticizer such as DEHP sits hundreds of times above the line and needs the justification of point 10.4.2, while a residue at the reported level sits far below it and is judged by its dose (Chapters 14 and 15).
- Assumptions. The numbers fix only the amounts. Whether a given residue is a substance that point 10.4.1 lists depends on its classification, which this chapter does not set out.
Above the line, a justification and a label
Above the line, the manufacturer has to argue for the substance, and point 10.4.2 sets out four parts of the argument. The first is "an analysis and estimation of potential patient or user exposure to the substance", which is the estimate Chapter 15 makes from the amount released. The second is "an analysis of possible alternative substances, materials or designs". The third explains why those alternatives would not serve, by their effect on the device's function, its performance and its benefit–risk balance, vulnerable patient groups included. The fourth draws, "where applicable and available", on "the latest relevant guidelines", and for phthalates those are the guidelines of point 10.4.3. The justification thus weighs the patient's exposure against what a substitute would change.
For phthalates the guidelines exist because the regulation called for them. As adopted, point 10.4.3 asked for a mandate to a scientific committee "by 26 May 2018", for guidelines "ready before 26 May 2020" and for updates "at least every five years". SCHEER, a scientific committee of the European Commission, adopted guidelines on the benefit–risk assessment of phthalates in devices in 2019. It adopted their update on 14 June 2024, and the update was published on 17 June 2024. The update covers phthalates that are CMR or endocrine-disrupting, DEHP in flexible PVC among them (Chapter 4). An amendment of 26 November 2025, Regulation (EU) 2025/2457, replaced point 10.4.3. The new point has the Commission ask the European Chemicals Agency, ECHA, to prepare and update the guidelines "when deemed appropriate based on the latest scientific evidence, but at least every 5 years".
A substance kept above the line is also declared. Point 10.4.5 requires its presence to be labeled on the device itself or on the packaging of each unit, or both, or where appropriate on the sales packaging, with the list of such substances. Where the device's intended use includes treating children, pregnant or breastfeeding women or other patient groups considered particularly vulnerable to such substances, the instructions for use give information on the residual risks for those groups and, if applicable, on precautionary measures. The label is the part of the decision that a clinician choosing a device for such a patient can read.
Harmonized standards give a presumption of conformity
A requirement such as point 10.2 states what a device must achieve, and a standard supplies a way to show it. A harmonized standard is a European standard, an EN, whose reference the Commission has cited in the Official Journal of the EU under the regulation. A device that meets it has a presumption of conformity: it is taken to meet the requirements that the standard covers. Following a harmonized standard is "one voluntary means of conforming", as the catalogue description of the 2025 amendment to EN ISO 10993-5 puts it. That amendment adds the annex relating EN ISO 10993-5 to the MDR. The Official Journal, not the Commission's summary list, is the legal reference for which standards are cited.
The EU's list differs, part by part, from FDA's. EN ISO 10993-1:2025 was cited in the Official Journal on 17 June 2026 with no restriction printed, while FDA recognizes the same edition only in part (Chapter 26). The parts on cytotoxicity, sensitization, tolerable intakes, chemical characterization and irritation, parts 5, 10, 17, 18 and 23, are cited in European editions dated 2009 to 2023, four of them with later amendments. For part 12, on preparing samples, and for parts 17 and 23, the text without its 2025 amendment loses its presumption on 15 December 2027.
The four parts of ISO 18562 have been cited in their 2024 editions since 30 January 2026. Parts 6 and 7 of EN ISO 10993, on implantation tests and on ethylene oxide residuals, have been cited in their 2026 editions since 10 November 2026 (Chapters 7 and 9). No edition of part 3, on genotoxicity, or of part 11, on systemic toxicity, is cited, so following either part gives a file no presumption of conformity.
The notified body reviews the evaluation
A notified body is a conformity assessment body designated under the regulation. Where a device's assessment involves one, it reviews the manufacturer's technical documentation, the file that shows how the device meets Annex I. The biological evaluation in that file is the plan, chemistry, risk estimate and test reports of Chapter 22, with any justification under point 10.4.2. The MDR "requires that manufacturers must demonstrate the identification, assessment and control of biological risks", TÜV NORD, a notified body, writes. On that account, the notified body reads the evaluation as an argument about risk.
Once conformity is shown, the manufacturer affixes the CE marking, the mark by which a manufacturer indicates that a device conforms to the requirements of the regulation that apply to it. Article 20 of the MDR requires the marking to be affixed visibly, legibly and indelibly to the device or to its sterile packaging. Where applicable, the identification number of the notified body responsible for the conformity assessment follows the marking, so the mark itself identifies the body that assessed the device. This book's EU file for the running device is an illustration, and it is written for the notified body's review that comes before the marking.
For each part of the gas pathway and each part that enters the body, take the substances the chemistry names (Chapters 12 and 13) and mark those classified as CMR in category 1A or 1B or identified as endocrine disruptors. Compare each marked substance's concentration in its part or material with 0.1 % by weight. Above the line, write the justification from the exposure estimate of Chapter 15, the alternatives considered and, for a phthalate, SCHEER's 2024 guidelines, and label the device. Cite each EN ISO part by the edition in the Official Journal on the file's date, and argue genotoxicity and systemic toxicity without a presumption.
- Annex I of the MDR asks for materials chosen particularly as regards toxicity, for the risk from contaminants and residues to be minimized, and for devices safe with the substances they contact, gases included.
- Point 10.4.1 allows a CMR substance of category 1A or 1B, or an identified endocrine disruptor, above 0.1 % by weight only where justified. It covers a device that is invasive and in direct contact with the body, one that administers substances, gases included, to or from the body, and one that transports or stores them to be administered to the body. The running device's gas pathway falls under it.
- The justification estimates the exposure, weighs alternatives and uses the latest relevant guidelines, which for phthalates are SCHEER's update of 14 June 2024. A substance above the line is labeled.
- A cited standard gives a presumption of conformity with the requirements it covers. As of November 2026 the EU cites EN ISO 10993-1:2025 with no restriction printed and parts 6 and 7 in their 2026 editions, but no edition of part 3 or part 11.
Let's Talk